---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-007999"
form_type: "8-K"
ticker: null
cik: "0001600132"
company_name: "Bellerophon Therapeutics, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:01:46.120189+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Bellerophon issues special voting preferred stock, reschedules special meeting to approve dissolution

## Summary
- Issued one share of Series A Preferred Stock for $1.00 with votes equal to outstanding common stock, but only on dissolution proposals.
- Special meeting rescheduled to March 1, 2024 to vote on dissolution; new record date February 5, 2024.
- Subscription agreement acknowledges limited cash and substantial doubt about going concern; company expects to dissolve.
- Series A Preferred is non-convertible, pays no dividends, and is redeemable at any time for $0.01.

## SEC filing metadata
- accession: 0001104659-24-007999
- form_type: 8-K
- cik: 0001600132
- company_name: Bellerophon Therapeutics, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600132/000110465924007999/0001104659-24-007999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600132/000110465924007999/tm244367d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-007999
- JSON: https://secwatch.observer/filing/0001104659-24-007999.json
- Plain text: https://secwatch.observer/filing/0001104659-24-007999.txt

## Key facts
- Governance Changes
  Bellerophon Therapeutics, Inc.: Filed certificate of designation for Series A Preferred Stock establishing rights, preferences, privileges, and restrictions (effective 2024-01-25).
  - Change: charter amendment
  - Effective: 2024-01-25
  source text: On January 25, 2024, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of the State of Delaware designating, effective as of the time of filing, the rights, preferences, privileges and restrictions of one share of Series A Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465924007999/0001104659-24-007999-index.htm
- Material Agreements
  Bellerophon Therapeutics, Inc. entered into Subscription and Investment Representation Agreement with a single accredited investor valued at $1.00 in cash (effective 2024-01-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a single accredited investor
  - Value: $1.00 in cash
  - Effective: 2024-01-25
  source text: On January 25, 2024, Bellerophon Therapeutics, Inc. (the "Company") entered into a Subscription and Investment Representation Agreement (the "Subscription Agreement") with a single accredited investor (the "Subscriber"), pursuant to which the Company agreed to issue and sell one share of the Company's Series A Preferred Stock, par value $0.01 per share (the "Series A Preferred Stock"), to the Subscriber for $1.00 in cash.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465924007999/0001104659-24-007999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.